Sedative may have better outcomes than common medication for ICU patients on respirator

December 11, 2007

Intensive care unit patients on respirators who were sedated with the drug dexmedetomidine had more days alive without delirium or coma and better sedation compared to patients treated with the recommended drug lorazepam, according to a study in the December 12 issue of JAMA.

Benzodiazepine drugs, such as lorazepam, are routinely administered to mechanically ventilated (respirators) patients to reduce pain and anxiety and to allow patients to tolerate invasive procedures in the intensive care unit (ICU). But these medications may also increase mechanical ventilation time, ICU length of stay and the risk of developing acute brain dysfunction, i.e., delirium and coma, according to background information in the article. The medication dexmedetomidine induces sedation via different central nervous system receptors than the benzodiazepine drugs and may lower the risk of acute brain dysfunction.

Pratik P. Pandharipande, M.D., M.S.C.I., of Vanderbilt University Schools of Medicine and Nursing, Nashville, Tenn., and colleagues conducted a study to determine if dexmedetomidine, when compared with benzodiazepine drugs, reduces the duration of delirium and coma while effectively sedating mechanically ventilated ICU patients. The randomized controlled trial included 106 adult ICU patients who were mechanically ventilated between August 2004 and April 2006. Patients were sedated with dexmedetomidine or lorazepam for as many as 120 hours.

The researchers found that dexmedetomidine patients had more days alive without delirium or coma (median [midpoint], 7 vs. 3). About 30 percent fewer patients experienced coma in the dexmedetomidine group than in the lorazepam group (63 percent vs. 92 percent). Nonsignificant differences were noted between the dexmedetomidine and lorazepam groups in death at 28-days (17 percent vs. 27 percent) and ventilator-free days (22 days vs. 18 days alive and free of mechanical ventilation).

A higher but nonsignificant percentage of patients in the dexmedetomidine group were able to complete post-ICU neuropsychological testing. Patients administered dexmedetomidine spent more time near the targeted level of sedation compared with patients sedated with lorazepam (median percentage of days, 80 percent vs. 67 percent). The 12-month time to death in the dexmedetomidine vs. the lorazepam group was 363 vs. 188 days, respectively.

"In this double-blind, randomized controlled trial, dexmedetomidine was more effective than lorazepam for achieving sustained sedation of mechanically ventilated medical and surgical ICU patients. Dexmedetomidine-treated ICU patients had 4 more days alive and without delirium or coma, significantly higher accuracy at meeting the stated sedation goals, and no added cost of care, as measured using data obtained at the largest enrolling site," the authors conclude.
-end-
'

(JAMA. 2007;298(22):2644-2653. Available pre-embargo to the media at www.jamamedia.org)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

The JAMA Network Journals

Related Delirium Articles from Brightsurf:

Delirium could be an early marker of COVID-19
Delirium accompanied by fever could be an early symptom of COVID-19.

Delirium a key sign of COVID-19 in frail, older people
A new analysis of data from researchers at King's College London using information from the COVID Symptom Study app and patients admitted to St Thomas' Hospital in London, has shown that delirium - a state of acute confusion associated with a higher risk of serious illness and death - is a key symptom of COVID-19 in frail, older people.

Does having Alzheimer's disease and dementia affect severity of delirium?
Recently, researchers published findings from the Better Assessment of Illness (BASIL) study, in the Journal of the American Geriatrics Society.

Scientists find new link between delirium and brain energy disruption
Scientists have discovered a new link between impaired brain energy metabolism and delirium -- a disorienting and distressing disorder particularly common in the elderly and one that is currently occurring in a large proportion of patients hospitalized with COVID-19.

Delirium may cause long term cognitive decline
A new meta-analysis of 24 observational studies from researchers at Columbia University Vagelos College of Physicians and Surgeons found that delirium may cause significant long-term cognitive decline.

Is delirium associated with long-term cognitive decline?
The results of 23 studies were combined to examine whether an episode of delirium is a risk factor for long-term cognitive decline.

Researchers work to better measure delirium severity in older patients
In a study published in Dementia and Geriatric Cognitive Disorder, researchers reported on their effort to improve and validate tools used to assess the severity of a condition called delirium, an acute confusional state often experienced by older hospitalized patients.

Coronavirus infections may lead to delirium and potentially PTSD
People taken ill by coronavirus infections may experience psychiatric problems while hospitalized and potentially after they recover, suggests an analysis of past research led by the UCL Institute of Mental Health with King's College London collaborators, published in The Lancet Psychiatry.

Music shows promise in decreasing delirium in critically ill patients
Mechanically ventilated ICU patients -- more than a million adults annually in the US -- are at increased risk for delirium, which is associated with prolonged ICU stays, higher healthcare costs and increased mortality.

Scientists isolate biomarkers that can identify delirium risk and severity
Regenstrief Institute and Indiana University School of Medicine researchers have identified blood-based biomarkers associated with both delirium duration and severity in critically ill patients.

Read More: Delirium News and Delirium Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.